The UNE-EN ISO 9001:2015 certification in of the technical Units of the CNIC ensures the quality and consistency of their processes, continuously improves efficiency, and enhances their credibility and global competitiveness. It helps manage risks, optimize resources, and ensure regulatory compliance, which builds trust with clients and collaborators. Furthermore, it enables the technical Units to operate more efficiently and in an organized manner, better positioning them in the scientific field and attracting more opportunities for collaboration
Mission
Supporting translational research: Provide state-of-the-art viral vectors (retrovirus, lentivirus, AAV) and novel gene therapy tools to accelerate biomedical research and therapeutic development.
Innovative service portfolio: Expand the scope of services offered by developing phage-display antibody-nanobody libraries, tailored for diverse research and clinical applications.
Collaborative excellence: Foster collaborations with academia, healthcare institutions, and industry to translate scientific discoveries into therapeutic solutions.
Education and training: Train the next generation of researchers and technicians in viral vector technology and gene therapy to address future challenges in the field.
Vision
Leadership in gene therapy innovation: Become a national and international reference Viral Vector Unit (ViVU) for viral vector production and advanced genetic tools, driving the future of gene therapy.
Cutting-edge technology and development: Lead the design of novel AAV capsids, advanced gene delivery platforms, and antibody-nanobody phage display libraries, fostering innovative solutions for unmet medical needs.
Sustainable and scalable services: Establish a sustainable infrastructure for scalable, high-quality viral vector production, enabling widespread use in research and translational medicine.
Quality Policy
High-quality standards: Commit to producing viral vectors and phage-display libraries under rigorous quality control processes to ensure consistency, reliability, and compliance with research and clinical-grade standards.
Regulatory compliance: Adhere to national and international regulatory frameworks, especially for gene therapy tools, ensuring safety, ethical responsibility, and reproducibility.
Continuous improvement: Embrace a culture of continuous learning and process optimization to incorporate cutting-edge advancements and improve operational efficiency.
Customer-centric approach: Focus on the needs of the research and medical communities, delivering customized, scalable, and high-value solutions tailored to evolving scientific and therapeutic goals.
Environmental responsibility: Implement sustainable practices in the development and production of viral vectors to minimize environmental impact and contribute to global sustainability goals.
